

# **Quality Measure**

# Appropriateness of Referral of Node-Positive Mastectomy Patients to Radiation Oncology

## **National Quality Strategy Domain**

- 1. Effective clinical care
- 2. Communication
- 3. Care coordination

## **Measure Type**

Process

## **Description**

Percent of patients undergoing mastectomy for node positive breast cancer with referral to radiation oncology.

#### **Numerator**

Number of node positive breast cancer patients undergoing mastectomy with documentation of radiation treatment discussion and/or referral to radiation oncology.

#### **Denominator**

Number of node positive breast cancer patients undergoing mastectomy.

#### **Denominator Exclusions**

Stage 4 breast cancer patients and node positive patients who undergo breast conserving surgery. Patient was presented at multi-disciplinary conference and decision was made not to refer.

#### **Denominator Exceptions**

Attempted discussion but patient refuses discussion or referral.

#### Rationale

All patients found to be node positive after mastectomy for breast cancer should be provided with a discussion of the benefits and risks of post-mastectomy radiation by either their

surgeon and/or a radiation oncologist. There is high level evidence of the benefit of radiation in reducing local regional cancer recurrence and improving overall survival in patients undergoing mastectomy who have four or more nodes positive. There is some evidence but less uniformity of opinion of similar benefit for radiation therapy in patients with 1-3 nodes positive. Current NCCN guidelines recommend use of post mastectomy radiation in patients with 4 or more positive nodes and to "strongly consider" radiation in patients with 1-3 nodes positive. The "consideration or administration" of radiation following mastectomy in women with  $\geq$  4 positive lymph nodes is a quality measure for the Commission on Cancer's RQRS program.

#### **Date Endorsed**

**Initially Endorsed:** Feb 26, 2015 **Revised:** Dec 7, 2015; Sep 17, 2020

## - References -

- The Early Breast Cancer Trialists' Collaborative Group (EBCTCG), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet*. 2014 Jun 21;383(9935):2127-35.
- 2. Commission on Cancer Program Practice Profile Reports (CP3R). Accessible at <a href="https://www.facs.org/quality-programs/cancer/ncdb/qualitytools/cp3r">https://www.facs.org/quality-programs/cancer/ncdb/qualitytools/cp3r</a>
- McBride A , Allen P, Woodward W, Kim M, Kuerer HM, Drinka EK, Sahin A, Strom EA, Buzdar A, Valero V, Hortobagyi GN, Hunt KK, Buchholz T. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2): 392-8
- 2014 NCCN Guidelines for Breast Cancer Treatment. Accessible at www.nccn.org
- Moo TA, McMillan R, Lee M, Stempel M, Patil S, Ho A, El-Tamer M. Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes. *Ann Surg Oncol.* 2013 Oct;20(10):3169-74.